Axon Enterprise, Inc. (NASDAQ:AXON) Director Sells $66,120.00 in Stock

Axon Enterprise, Inc. (NASDAQ:AXON) Director Michael Garnreiter sold 87 shares of the firm’s stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $760.00, for a total value of $66,120.00. Following the completion of the transaction, the director now owns 24,653 shares of the company’s stock, valued at approximately $18,736,280. This represents a 0.35% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Michael Garnreiter also recently made the following trade(s):

• On Wednesday, June 4th, Michael Garnreiter sold 5,913 shares of Axon Enterprise stock. The shares were sold at an average price of $760.00, for a total value of $4,493,880.00.

Axon Enterprise Price Performance

Shares of NASDAQ AXON opened at $780.00 on Thursday. The stock has a market capitalization of $60.72 billion, a PE ratio of 201.55, a P/E/G ratio of 5.17 and a beta of 1.24. The company has a debt-to-equity ratio of 0.32, a current ratio of 2.96 and a quick ratio of 2.63. The business has a fifty day moving average price of $633.63 and a two-hundred day moving average price of $613.89. Axon Enterprise, Inc. has a fifty-two week low of $276.23 and a fifty-two week high of $780.62.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $1.41 earnings per share for the quarter, beating the consensus estimate of $1.34 by $0.07. The firm had revenue of $603.63 million during the quarter, compared to analysts’ expectations of $585.67 million. Axon Enterprise had a return on equity of 7.50% and a net margin of 15.37%. The company’s quarterly revenue was up 31.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.15 EPS. As a group, equities analysts predict that Axon Enterprise, Inc. will post 5.8 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Axon Enterprise

Several hedge funds and other institutional investors have recently added to or reduced their stakes in AXON. Savant Capital LLC raised its holdings in shares of Axon Enterprise by 5.7% during the 4th quarter. Savant Capital LLC now owns 1,080 shares of the biotechnology company’s stock worth $642,000 after buying an additional 58 shares in the last quarter. Principal Securities Inc. raised its holdings in shares of Axon Enterprise by 255.7% during the 4th quarter. Principal Securities Inc. now owns 1,085 shares of the biotechnology company’s stock worth $645,000 after buying an additional 780 shares in the last quarter. Empowered Funds LLC raised its holdings in shares of Axon Enterprise by 89.2% during the 4th quarter. Empowered Funds LLC now owns 1,871 shares of the biotechnology company’s stock worth $1,112,000 after buying an additional 882 shares in the last quarter. WESPAC Advisors SoCal LLC raised its holdings in shares of Axon Enterprise by 20.1% during the 4th quarter. WESPAC Advisors SoCal LLC now owns 3,418 shares of the biotechnology company’s stock worth $2,031,000 after buying an additional 573 shares in the last quarter. Finally, Xponance Inc. raised its holdings in shares of Axon Enterprise by 3.5% during the 4th quarter. Xponance Inc. now owns 16,469 shares of the biotechnology company’s stock worth $9,788,000 after buying an additional 560 shares in the last quarter. 79.08% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms have weighed in on AXON. Needham & Company LLC raised their price target on Axon Enterprise from $600.00 to $750.00 and gave the company a “buy” rating in a research note on Thursday, May 8th. Northcoast Research downgraded Axon Enterprise from a “buy” rating to a “neutral” rating in a research note on Wednesday, February 19th. Bank of America lifted their target price on Axon Enterprise from $750.00 to $895.00 and gave the stock a “buy” rating in a research note on Wednesday. Barclays lifted their target price on Axon Enterprise from $726.00 to $735.00 and gave the stock an “overweight” rating in a research note on Friday, May 9th. Finally, Craig Hallum downgraded Axon Enterprise from a “buy” rating to a “cautious” rating in a research note on Monday, March 10th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and ten have given a buy rating to the company. According to MarketBeat.com, Axon Enterprise presently has an average rating of “Moderate Buy” and a consensus target price of $699.55.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.